SCHEMBL19084586

SCHEMBL19084586

O=c1cc(-c2ccc(Br)cc2)[nH]c2c(-c3ccc(Cl)cc3)c(C(F)(F)F)nn12

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ARF6 P62330 8/20 0.53
PLAT P00750 1/20 0.52
PSD A5PKW4 6/20 0.48
KCNQ3 O43525 2/20 0.40
KCNQ2 O43526 2/20 0.40
GCGR P47871 1/20 0.38
MAPK14 Q16539 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
CRHBP P24387 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
CRHR2 Q13324 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19084538 0.94 ARF6 (0.58) ARF6PLATPSDKCNQ3KCNQ2
SCHEMBL1278782 0.90 ARF6 (0.58) ARF6PLATPSDKCNQ3KCNQ2
SCHEMBL1279352 0.90 ARF6 (0.59) ARF6PLATPSDKCNQ3KCNQ2
SCHEMBL19084679 0.89 PSD (0.52) ARF6PLATPSDKCNQ3KCNQ2
SCHEMBL19084547 0.89 ARF6 (0.53) ARF6PLATPSDKCNQ3KCNQ2
SCHEMBL19084660 0.88 ARF6 (0.53) ARF6PLATPSDKCNQ3KCNQ2
SCHEMBL17298733 0.86 ARF6 (0.63) ARF6PLATPSDKCNQ3KCNQ2
SCHEMBL19084662 0.85 ARF6 (0.58) ARF6PLATPSDKCNQ3KCNQ2
SCHEMBL19084678 0.85 PSD (0.52) ARF6PLATPSDMEN1ALDH1A1
SCHEMBL19084590 0.83 PSD (0.53) ARF6PLATPSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 ARF6 1/4885PLAT 3989/4885PSD 211/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 ARF6 1/4885PLAT 3989/4885PSD 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.